Skip to main content
Premium Trial:

Request an Annual Quote

Reproductive Health Science Inks PGS Distribution Deal with Tani Medikal

NEW YORK (GenomeWeb) – Australian biotech firm Reproductive Health Science said that it has signed a three-year exclusive agreement with Tani Medikal for the distribution of RHS's EmbryoCellect kit for pre-implantation genetic screening for in vitro fertilization.

Tani Medikal is based in Turkey and will distribute EmbryoCellect in Turkey, Azerbaijan, Georgia, Turkish Republic of Northern Cyprus, Kosovo, Macedonia, and North Iraq (Kurdish region).

EmbryoSelect uses microarray-based comparative genomic hybridization to compare the number of chromosomes in a sample cell to a known reference sample, providing a way to count the number of chromosomes in the test cell and detect whole chromosome aneuploidy.

Adelaide-based RHS went public in April after raising A$3 million (US$2.8 million at the time) and completing a reverse merger with AO Energy, a publicly traded mining company.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.